Ownership and insider activity for Amylyx Pharmaceuticals, Inc. (AMLX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor.
Price
| Price | $32.63 |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Bedrosian Camille L | S-Sale | 7,947 | $256K |
| 2026-09-10 | Bedrosian Camille L | S-Sale | 2,081 | $69K |
| 2026-09-10 | FRATES JAMES M | S-Sale | 9,768 | $315K |
| 2026-09-10 | FRATES JAMES M | S-Sale | 1,042 | $35K |
| 2026-09-10 | Mazzariello Gina | S-Sale | 9,525 | $309K |
| 2026-09-10 | Mazzariello Gina | S-Sale | 11 | $367 |
| 2026-09-10 | Klee Justin B. | S-Sale | 29,025 | $933K |
| 2026-09-10 | Klee Justin B. | S-Sale | 1,439 | $48K |
| 2026-09-10 | Cohen Joshua B | S-Sale | 29,545 | $950K |
| 2026-09-10 | Cohen Joshua B | S-Sale | 919 | $30K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1M | $12.9M | $50.2M | $62.5M | $170.2M | $77.4M | $226.7M |
| Short-term Investments | 0 | 0 | $45.9M | $284.4M | $201.2M | $99.1M | $90.3M |
| Receivables | 0 | 0 | 0 | $15.3M | $40.0M | $447000 | $88000 |
| Inventory | 0 | 0 | 0 | $9.8M | $38.3M | 0 | 0 |
| Total Current Assets | $3.2M | $13.6M | $105.0M | $382.1M | $464.7M | $189.4M | $323.7M |
| Property, Plant & Equipment | 0 | $151000 | $474000 | $8.1M | $6.4M | $2.7M | $5.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $3.2M | $14.1M | $105.6M | $391.5M | $517.5M | $193.6M | $332.6M |
| Accounts Payable | $2.2M | $3.6M | $4.4M | $6.3M | $22.1M | $2.9M | $3.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.5M | $7.3M | $17.4M | $46.6M | $82.0M | $28.4M | $22.7M |
| Long-term Debt | $14.9M | $1.4M | 0 | 0 | 0 | 0 | $4.7M |
| Total Liabilities | $28.6M | $80.8M | $256.8M | $50.8M | $84.0M | $28.9M | $27.4M |
| Retained Earnings | -$25.6M | -$67.9M | -$155.8M | -$354.2M | -$304.9M | -$606.7M | -$751.4M |
| Total Equity | -$25.4M | -$66.7M | -$151.2M | $340.6M | $433.4M | $164.8M | $305.3M |
| Total Debt | $14.9M | $1.4M | 0 | $6.3M | $4.2M | $2.0M | $6.0M |
| Net Debt | $11.9M | -$11.5M | -$96.1M | -$340.7M | -$367.1M | -$174.5M | -$311.0M |
| Working Capital | -$1.3M | $6.3M | $87.6M | $335.5M | $382.6M | $161.0M | $301.0M |
Related companies: ATAI · CVAC · IMTX · INBX · NKTR · ORIC · PGEN
Explore sector: Healthcare · Biotechnology
More sections of AMLX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks